HEPATITIS B AKUT PADA LAKI-LAKI 31 TAHUN
DOI:
https://doi.org/10.31004/jkt.v6i4.51538Keywords:
Hepatitis B, kasus klinis, infeksi hati, tatalaksana, TenofovirAbstract
Hepatitis B merupakan infeksi hati yang masih menjadi masalah kesehatan global dengan angka mortalitas tinggi akibat sirosis dan karsinoma hepatoseluler. Di Indonesia, prevalensi HBsAg masih cukup tinggi, terutama pada kelompok usia produktif dengan perilaku seksual berisiko. Seorang laki-laki 31 tahun datang dengan keluhan nyeri perut kanan atas, mual muntah, lemas, ikterus, urin gelap, dan feses pucat. Pemeriksaan fisik menunjukkan ikterus dan nyeri tekan di regio kanan atas. Laboratorium memperlihatkan peningkatan SGOT (403 U/L), SGPT (504 U/L), bilirubin total (9,56 mg/dL), serta HBsAg positif. Pasien memiliki riwayat hubungan seksual tanpa proteksi, tanpa riwayat penggunaan jarum suntik atau konsumsi alkohol. Diagnosis ditegakkan berdasarkan anamnesis, pemeriksaan fisik, dan hasil laboratorium sesuai kriteria hepatitis B akut fase ikterik. Tatalaksana mengikuti pedoman WHO dan EASL, berupa terapi suportif dan pemberian antivirus Tenofovir 300 mg per hari, disertai edukasi mengenai pencegahan penularan dan gaya hidup sehat. Setelah terapi dan pemantauan fungsi hati, pasien menunjukkan perbaikan klinis tanpa tanda gagal hati fulminan. Peningkatan enzim hati berangsur menurun, dengan prognosis baik dan kemungkinan resolusi spontan. Pemantauan serologi dilakukan untuk mencegah kronisitas dan komplikasi jangka panjang. Hepatitis B akut dapat dikenali melalui anamnesis dan pemeriksaan laboratorium yang tepat. Hubungan seksual berisiko merupakan faktor penularan utama pada kasus ini. Penatalaksanaan sesuai pedoman global dengan terapi antivirus dan edukasi pasien memberikan hasil klinis yang baik.References
European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer. (2018). EASL–EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69(1), 182–236.
Lampertico, P. et al. (2023). EASL Clinical Practice Guidelines: Hepatitis B Virus Infection. Journal of Hepatology, 79(3), 574–622.
Lazarevic, I., & others. (2023). Clinical Utility of Quantitative HBV Core Antibodies for Diagnosis and Management. Viruses, 15(2), 373.
Mengchao, A., & others. (2022). Clinical Significance of Serum HBV DNA Levels in the Natural History and Management of Chronic Hepatitis B Infection. Frontiers in Immunology, 13, 1034532.
National Center for Biotechnology Information (NCBI). (2025). Overview of Viral Hepatitis. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/
RI, K. K. (2023). Profil Kesehatan Indonesia. Nan, nan(nan), nan.
Sarin, S. K. et al. (2020). Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B. Hepatology International, 14(5), 1–48.
Schweitzer, A. et al. (2023). Hepatitis B Virus Infection: Epidemiology, Pathogenesis and Treatment. Lancet Gastroenterology and Hepatology, 8(4), 345–360.
Setiawan, Y. et al. (2022). Clinical Profile and Outcome of Acute Hepatitis B Infection Among Young Adults in Indonesia: A Case Series. Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 23(2), 45–52.
Seto, W. K. et al. (2024). Chronic Hepatitis B Virus Infection. Lancet, 398(10310), 1113–1124.
Tahmid, T. et al. (2022). Does ESG initiatives yield greater firm value and performance? New evidence from European firms. Cogent Business and Management, 9(1). https://doi.org/10.1080/23311975.2022.2144098
Tanjung, M. (2023). Cost of capital and firm performance of ESG companies: what can we infer from COVID-19 pandemic? Sustainability Accounting, Management and Policy Journal, 14(6), 1242–1267. https://doi.org/10.1108/SAMPJ-07-2022-0396
Terrault, N. A. et al. (2023). Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2023 Guidance. Hepatology, 78(1), 1–38.
World Health Organization (WHO). (2022). Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO.
World Health Organization (WHO). (2024). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. WHO.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Vivian Viontika, Shelvi Febrianti, Deva Bachtiar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
